A citation-based method for searching scientific literature

Libin Zhang, Yanhui Chen, Han Wang, Zheyuan Xu, Yang Wang, Sixing Li, Jun Liu, Yun Chen, Hongli Luo, Lijia Wu, Ying Yang, Henghui Zhang, Hao Peng. J Immunother Cancer 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Aaron M Goodman, Shumei Kato, Lyudmila Bazhenova, Sandip P Patel, Garrett M Frampton, Vincent Miller, Philip J Stephens, Gregory A Daniels, Razelle Kurzrock. Mol Cancer Ther 2017
975
100

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson, Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L Sauter, Natasha Rekhtman,[...]. J Clin Oncol 2018
639
100

Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts.
Daniel Kazdal, Volker Endris, Michael Allgäuer, Mark Kriegsmann, Jonas Leichsenring, Anna-Lena Volckmar, Alexander Harms, Martina Kirchner, Katharina Kriegsmann, Olaf Neumann,[...]. J Thorac Oncol 2019
34
100

Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.
Beatriz M Carreno, Vincent Magrini, Michelle Becker-Hapak, Saghar Kaabinejadian, Jasreet Hundal, Allegra A Petti, Amy Ly, Wen-Rong Lie, William H Hildebrand, Elaine R Mardis,[...]. Science 2015
688
100


Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Arjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, Thomas Powles, Daniel P Petrylak, Joaquim Bellmunt, Yohann Loriot, Andrea Necchi, Jean Hoffman-Censits, Jose Luis Perez-Gracia,[...]. Lancet 2017
100

The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel.
Wu Zhuang, Junxun Ma, Xudong Chen, Guoqiang Wang, Jing Lu, Yanan Chen, Hua Dong, Shangli Cai, Yuzi Zhang, Xiaochen Zhao,[...]. J Cancer 2018
15
100

Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.
Barzin Y Nabet, Mohammad S Esfahani, Everett J Moding, Emily G Hamilton, Jacob J Chabon, Hira Rizvi, Chloe B Steen, Aadel A Chaudhuri, Chih Long Liu, Angela B Hui,[...]. Cell 2020
53
100

Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients.
Florence Koeppel, Steven Blanchard, Cécile Jovelet, Bérengère Genin, Charles Marcaillou, Emmanuel Martin, Etienne Rouleau, Eric Solary, Jean-Charles Soria, Fabrice André,[...]. PLoS One 2017
59
100

Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study.
Haiping Jiang, Yulong Zheng, Jiong Qian, Chenyu Mao, Xin Xu, Ning Li, Cheng Xiao, Huan Wang, Lisong Teng, Hui Zhou,[...]. Cancer Immunol Immunother 2021
8
100


Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Willy Hugo, Jesse M Zaretsky, Lu Sun, Chunying Song, Blanca Homet Moreno, Siwen Hu-Lieskovan, Beata Berent-Maoz, Jia Pang, Bartosz Chmielowski, Grace Cherry,[...]. Cell 2016
100

Effect of fixatives and tissue processing on the content and integrity of nucleic acids.
Mythily Srinivasan, Daniel Sedmak, Scott Jewell. Am J Pathol 2002
763
100

Mutational Landscape and Sensitivity to Immune Checkpoint Blockers.
Roman M Chabanon, Marion Pedrero, Céline Lefebvre, Aurélien Marabelle, Jean-Charles Soria, Sophie Postel-Vinay. Clin Cancer Res 2016
113
100

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Zachary R Chalmers, Caitlin F Connelly, David Fabrizio, Laurie Gay, Siraj M Ali, Riley Ennis, Alexa Schrock, Brittany Campbell, Adam Shlien, Juliann Chmielecki,[...]. Genome Med 2017
100

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.
Whijae Roh, Pei-Ling Chen, Alexandre Reuben, Christine N Spencer, Peter A Prieto, John P Miller, Vancheswaran Gopalakrishnan, Feng Wang, Zachary A Cooper, Sangeetha M Reddy,[...]. Sci Transl Med 2017
342
100

Assessment of the quality of DNA from various formalin-fixed paraffin-embedded (FFPE) tissues and the use of this DNA for next-generation sequencing (NGS) with no artifactual mutation.
Naoki Einaga, Akio Yoshida, Hiroko Noda, Masaaki Suemitsu, Yuki Nakayama, Akihisa Sakurada, Yoshiko Kawaji, Hiromi Yamaguchi, Yasushi Sasaki, Takashi Tokino,[...]. PLoS One 2017
48
100

Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yunfang Yu, Dongqiang Zeng, Qiyun Ou, Shengbo Liu, Anlin Li, Yongjian Chen, Dagui Lin, Quanlong Gao, Haiyu Zhou, Wangjun Liao,[...]. JAMA Netw Open 2019
82
100

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
Zhijie Wang, Jianchun Duan, Shangli Cai, Miao Han, Hua Dong, Jun Zhao, Bo Zhu, Shuhang Wang, Minglei Zhuo, Jianguo Sun,[...]. JAMA Oncol 2019
198
100

Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, David C Wedge, Samuel A J R Aparicio, Sam Behjati, Andrew V Biankin, Graham R Bignell, Niccolò Bolli, Ake Borg, Anne-Lise Børresen-Dale,[...]. Nature 2013
100

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Naiyer A Rizvi, Byoung Chul Cho, Niels Reinmuth, Ki Hyeong Lee, Alexander Luft, Myung-Ju Ahn, Michel M van den Heuvel, Manuel Cobo, David Vicente, Alexey Smolin,[...]. JAMA Oncol 2020
135
100

Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.
Gaurav Singal, Peter G Miller, Vineeta Agarwala, Gerald Li, Gaurav Kaushik, Daniel Backenroth, Anala Gossai, Garrett M Frampton, Aracelis Z Torres, Erik M Lehnert,[...]. JAMA 2019
151
100

Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors.
Zhijie Wang, Jianchun Duan, Guoqiang Wang, Jing Zhao, Jiachen Xu, Jiefei Han, Zhengyi Zhao, Jun Zhao, Bo Zhu, Minglei Zhuo,[...]. J Thorac Oncol 2020
26
100

Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, Taha Merghoub, Jianda Yuan, Jesse M Zaretsky, Alexis Desrichard, Logan A Walsh, Michael A Postow, Phillip Wong, Teresa S Ho,[...]. N Engl J Med 2014
100

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
Patrick M Forde, Jamie E Chaft, Kellie N Smith, Valsamo Anagnostou, Tricia R Cottrell, Matthew D Hellmann, Marianna Zahurak, Stephen C Yang, David R Jones, Stephen Broderick,[...]. N Engl J Med 2018
733
100

A Method to Evaluate the Quality of Clinical Gene-Panel Sequencing Data for Single-Nucleotide Variant Detection.
Chung Lee, Joon S Bae, Gyu H Ryu, Nayoung K D Kim, Donghyun Park, Jongsuk Chung, Sungkyu Kyung, Je-Gun Joung, Hyun-Tae Shin, Seung-Ho Shin,[...]. J Mol Diagn 2017
13
100

Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.
Lawrence J Jennings, Maria E Arcila, Christopher Corless, Suzanne Kamel-Reid, Ira M Lubin, John Pfeifer, Robyn L Temple-Smolkin, Karl V Voelkerding, Marina N Nikiforova. J Mol Diagn 2017
258
100

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
Matthew D Hellmann, Margaret K Callahan, Mark M Awad, Emiliano Calvo, Paolo A Ascierto, Akin Atmaca, Naiyer A Rizvi, Fred R Hirsch, Giovanni Selvaggi, Joseph D Szustakowski,[...]. Cancer Cell 2018
416
100

High-throughput DNA sequencing--concepts and limitations.
Martin Kircher, Janet Kelso. Bioessays 2010
279
100

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.
Zhong-Yi Dong, Wen-Zhao Zhong, Xu-Chao Zhang, Jian Su, Zhi Xie, Si-Yang Liu, Hai-Yan Tu, Hua-Jun Chen, Yue-Li Sun, Qing Zhou,[...]. Clin Cancer Res 2017
367
100

The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.
Yueping Jin, Hui Dong, Liliang Xia, Yi Yang, Yongqiang Zhu, Yan Shen, Huajun Zheng, Chengcheng Yao, Ying Wang, Shun Lu. J Thorac Oncol 2019
119
100

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.
Douglas B Johnson, Garrett M Frampton, Matthew J Rioth, Erik Yusko, Yaomin Xu, Xingyi Guo, Riley C Ennis, David Fabrizio, Zachary R Chalmers, Joel Greenbowe,[...]. Cancer Immunol Res 2016
284
100


Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
Biagio Ricciuti, Sasha Kravets, Suzanne E Dahlberg, Renato Umeton, Adem Albayrak, Safiya J Subegdjo, Bruce E Johnson, Mizuki Nishino, Lynette M Sholl, Mark M Awad. J Immunother Cancer 2019
41
100

Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens.
Judith N Müller, Markus Falk, Jatin Talwar, Nicole Neemann, Erika Mariotti, Miriam Bertrand, Tobias Zacherle, Sotirios Lakis, Roopika Menon, Christian Gloeckner,[...]. J Thorac Oncol 2017
29
100

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer.
Joshua E Reuss, Valsamo Anagnostou, Tricia R Cottrell, Kellie N Smith, Franco Verde, Marianna Zahurak, Mara Lanis, Joseph C Murray, Hok Yee Chan, Caroline McCarthy,[...]. J Immunother Cancer 2020
26
100

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Jonathan E Rosenberg, Jean Hoffman-Censits, Tom Powles, Michiel S van der Heijden, Arjun V Balar, Andrea Necchi, Nancy Dawson, Peter H O'Donnell, Ani Balmanoukian, Yohann Loriot,[...]. Lancet 2016
100

Tumor mutation burden in Chinese cancer patients and the underlying driving pathways of high tumor mutation burden across different cancer types.
Xiao-Dong Jiao, Xiao-Chun Zhang, Bao-Dong Qin, Dong Liu, Liang Liu, Jian-Jiao Ni, Zhou-Yu Ning, Ling-Xiang Chen, Liang-Jun Zhu, Song-Bing Qin,[...]. Ann Transl Med 2020
3
100

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website.
S Bamford, E Dawson, S Forbes, J Clements, R Pettett, A Dogan, A Flanagan, J Teague, P A Futreal, M R Stratton,[...]. Br J Cancer 2004
828
100

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.
David R Gandara, Sarah M Paul, Marcin Kowanetz, Erica Schleifman, Wei Zou, Yan Li, Achim Rittmeyer, Louis Fehrenbacher, Geoff Otto, Christine Malboeuf,[...]. Nat Med 2018
507
100

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Matthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong Seok Lee, Gregory A Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak Burgers, Pamela Salman,[...]. N Engl J Med 2018
100

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
Nadeem Riaz, Jonathan J Havel, Vladimir Makarov, Alexis Desrichard, Walter J Urba, Jennifer S Sims, F Stephen Hodi, Salvador Martín-Algarra, Rajarsi Mandal, William H Sharfman,[...]. Cell 2017
674
100


Reliable Analysis of Clinical Tumor-Only Whole-Exome Sequencing Data.
Sehyun Oh, Ludwig Geistlinger, Marcel Ramos, Martin Morgan, Levi Waldron, Markus Riester. JCO Clin Cancer Inform 2020
3
100

Implementing TMB measurement in clinical practice: considerations on assay requirements.
Reinhard Büttner, John W Longshore, Fernando López-Ríos, Sabine Merkelbach-Bruse, Nicola Normanno, Etienne Rouleau, Frédérique Penault-Llorca. ESMO Open 2019
112
100

Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions.
Albrecht Stenzinger, Jeffrey D Allen, Jörg Maas, Mark D Stewart, Diana M Merino, Madison M Wempe, Manfred Dietel. Genes Chromosomes Cancer 2019
81
100

Optimizing panel-based tumor mutational burden (TMB) measurement.
J Budczies, M Allgäuer, K Litchfield, E Rempel, P Christopoulos, D Kazdal, V Endris, M Thomas, S Fröhling, S Peters,[...]. Ann Oncol 2019
60
100

Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.
Yuting Liu, Jon Zugazagoitia, Fahad Shabbir Ahmed, Brian S Henick, Scott N Gettinger, Roy S Herbst, Kurt A Schalper, David L Rimm. Clin Cancer Res 2020
60
100

Guidance for laboratories performing molecular pathology for cancer patients.
Ian A Cree, Zandra Deans, Marjolijn J L Ligtenberg, Nicola Normanno, Anders Edsjö, Etienne Rouleau, Francesc Solé, Erik Thunnissen, Wim Timens, Ed Schuuring,[...]. J Clin Pathol 2014
108
100

Somatic mutation of LRP1B is associated with tumor mutational burden in patients with lung cancer.
Shaowei Lan, Hui Li, Ying Liu, Lixia Ma, Xianhong Liu, Yan Liu, Shi Yan, Ying Cheng. Lung Cancer 2019
11
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.